Eli Lilly and Company (LLY)
| Market Cap | 738.61B |
| Revenue (ttm) | 45.04B |
| Net Income (ttm) | 10.59B |
| Shares Out | 897.99M |
| EPS (ttm) | 11.71 |
| PE Ratio | 70.24 |
| Forward PE | 35.42 |
| Dividend | $6.00 (0.73%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 1,695,974 |
| Open | 820.00 |
| Previous Close | 821.67 |
| Day's Range | 817.43 - 829.78 |
| 52-Week Range | 711.40 - 972.53 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 1,000.53 (+21.64%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,000.53, which is an increase of 21.64% from the latest price.
News
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented a...
Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were p...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs a...
Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop
Eli Lilly & Co. (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
GLP-1 space will remain two player over the medium to long term, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to talk Novo Nordisk sinking on lighter-than-expected GLP-1 demand.
Here's one healthcare name this strategist says is buy, and another to avoid
In the latest Good Buy or Goodbye, Regan Capital chief investment officer Skyler Weinand joins Market Domination host Julie Hyman to break down which stock is a good buy and what stock should be avoid...
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks.
EU medicines regulator rejects Eli Lilly's Alzheimer's drug
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug Kisunla, saying the risk of serious brain swelling did not outweigh the treatment's small impact on slowing cogniti...
VIG: Index Rebalance Adds Eli Lilly To Bolster Dividend Growth In 2025
VIG's Index rebalanced last week and now counts Eli Lilly as its #5 holding with a 3.45% allocation. The ETF is on an impressive 11-year dividend growth streak. The Index yield dropped 0.04% to 1.81%,...
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Lilly adds Alzheimer's to online offerings
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose and care for patients with Alzheimer's disease, potentially boosting sales...
Checking in on the weight-loss drug space: Novo Nordisk, Eli Lilly, and others
Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here
Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock leveraged and inverse exchange-traded funds.
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
INDIANAPOLIS , March 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented a...
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approach...
Eli Lilly Shares Rise Over 2% After Key Signal
Eli Lilly & Co. (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
5 Stocks That Could Be The Next Nvidia
Everybody loves a great growth stock. We all know the stories of the incredible wealth delivered by fast-growing companies that keep growing for a long period of time.
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical ...
Novo Nordisk's $2 billion obesity deal
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss Eli Lilly's latest obesity pill trial.
Eli Lilly: Growth With Higher Margins
The Eli Lilly and Company investment thesis highlights a robust 2024 performance, driven by a strong pipeline and solid balance sheet, supporting a positive future outlook. The company's strong cash f...
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
Eli Lilly: A Safe Harbor Amid Market Volatility
My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and st...
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
The Investment Committee debate the latest Calls of the Day.